Celularity Vesalius peptide deal targets compounding pharmacies with no supply date

Celularity and Vesalius Longevity Labs said on October 29, 2026 that Celularity will become the exclusive finishing manufacturer for Vesalius peptide drug ingredients at its plant in Florham Park, New Jersey. The Celularity Vesalius peptide deal targets licensed US compounding pharmacies, but the companies gave no start date, volume or price, and they tied any sales to a future FDA decision. It arrived one day after HHS published an interim policy that lets small pharmacies compound six unapproved peptides from registered suppliers.

What Celularity and Vesalius agreed to build

Under the agreement, Celularity will take bulk peptide material made by outside suppliers and handle the later steps: purification, processing, analytical testing and final manufacturing into active pharmaceutical ingredients, known as APIs. The companies say the aim is a peptide process that meets current good manufacturing practice, with defined specifications, documented sourcing and records that trace each lot. Celularity, a Nasdaq listed cell therapy and biomaterials company, describes peptide API work as a new business line built on its biologics experience. Vesalius calls itself a peptide and longevity brand and says it runs a business to doctor to consumer model that includes telehealth and product fulfillment. The ingredients would carry the Peptual brand of Vesalius. GLP 1 receptor agonists and other weight loss peptides are excluded, the companies said.

No financial terms were disclosed. Celularity said the work creates an opportunity to grow revenue, and chief executive Robert Hariri called it "an important business opportunity for Celularity." Those are company expectations, not results. The joint company release lists in its risk section what still has to happen: the partners must agree on and fund product specific development plans and supply terms, finish technology transfer and process development, qualify test methods and manufacturing, reach commercial scale and obtain the needed registrations and licenses. It also warns that some peptides may not be eligible for the intended channels and that commercial supply "may be delayed indefinitely or may not occur." For anyone tracking domestic peptide manufacturing, this is a plan on paper, not a working supply line.

Why the supply waits on an FDA list

Federal law sets narrow terms for what a 503A compounding pharmacy may use. A bulk ingredient generally must meet a USP or National Formulary monograph, be part of an FDA approved drug, or appear on the 503A bulks list that the FDA builds through rulemaking, according to the HHS policy text. It must also come from an FDA registered establishment and carry a valid certificate of analysis. The companies said they intend to supply eligible ingredients to licensed compounding pharmacies if and when the FDA, after weighing advice from its Pharmacy Compounding Advisory Committee, adds covered peptides to that list. Until then, the release says, signing the agreement and finishing development work do not authorize any commercial release, distribution or use of a peptide API.

The release names no peptide, no bulk supplier, no start date and no price, so pharmacies have nothing concrete to plan around yet.

The advisory committee voted in July in favor of six peptides and against a seventh, emideltide, BioSpace reported. HHS went further on October 28 with a written policy saying it does not intend to act against state licensed pharmacies, federal facilities or licensed physicians that compound BPC 157, epitalon, KPV, MOTS-c, semax or TB 500 under set conditions while rulemaking continues. Our report on the HHS peptide compounding policy explains who is left out. The joint release does not mention this interim route and does not say whether the partners would supply under it. The release names no peptide, no bulk supplier, no start date and no price, so pharmacies have nothing concrete to plan around yet.

What the HHS peptide enforcement discretion policy asks of suppliers

The HHS peptide enforcement discretion conditions focus on the raw material. The bulk peptide must come from a facility registered with the FDA under section 510 and arrive with a certificate of analysis that reports identity, purity, potency and tests for contaminants such as endotoxins and heavy metals. The original manufacturer, not a later packer, relabeler or distributor, must be registered, comply with manufacturing rules and have its physical address listed on that certificate. Each product may contain only one listed peptide and must carry a compounded drug label. Compounders must report products made, serious adverse events and quality problems to the FDA and to states, and may pack only an FDA cleared syringe. HHS said the aim is to steer patients away from research use only peptides from foreign manufacturers.

That is the gap the Celularity Vesalius peptide deal says it wants to fill, yet key details are missing. Celularity would work from bulk peptide supplied by others, and the release does not name that supplier or say where it operates. Under the HHS text, the original manufacturer of the bulk substance is the firm that must be registered and named on the certificate. The release does not explain which company would hold that role for these ingredients, and it does not say whether the Florham Park site is registered with the FDA for API production. HHS also said it may revisit the policy if a safety signal or quality problem appears, and our earlier piece on the White House review explains why an enforcement pause is not an approval.

What changes for pharmacies patients and payers

For pharmacies, sourcing is the practical issue. The companies noted that the FDA has raised concerns about peptide APIs from unverified foreign sources and has urged compounders to check suppliers, understand the testing behind each lot and identify the original API maker. State regulators are watching too: the Ohio pharmacy board suspended a med spa drug license after inspectors found peptides from an unlicensed source. A US finishing site with lot records could ease that paperwork if it ever ships. "When the original manufacturer is unclear or testing records are incomplete, physicians and patients are left with questions that should be answered before a product is used," said Michael Roizen, chief scientific advisor at Vesalius. The Celularity Vesalius peptide deal does not yet supply any pharmacy.

For patients, nothing changes today. The peptides and APIs in the release are not FDA approved drugs, and compounded drugs are not reviewed by the FDA for safety, effectiveness or manufacturing quality before they reach the market, the companies stated. Making an ingredient in New Jersey, passing an inspection or holding a certificate of analysis does not amount to FDA approval either, the release adds. Prescribers should know that the FDA drug center recommended against listing BPC 157, TB 500, epitalon and semax, according to the HHS document. For payers, the release gives no price and does not mention insurance. Any access gain depends on regulators acting first, then on the partners building and qualifying a process that is not yet proven at commercial scale.

Conclusion

The Celularity Vesalius peptide deal is a plan for US finished peptide ingredients for compounding pharmacies, not a supply that exists today. It names no peptide, start date or price, and it waits on FDA action on the 503A bulks list. The HHS interim policy for six peptides sets firm rules on supplier records, and the open question is whether this partnership can meet them. We will report the first registration, product list or shipment if the companies disclose one.